The use of combination immunotherapies as front-line therapy for non-small-cell lung cancer

被引：7
作者：
Santana-Davila, Rafael [1 ]
Chow, Laura Q. M. [1 ]
机构：
[1] Univ Washington, Dept Med, Div Med Oncol, Seattle, WA 98195 USA
来源：
FUTURE ONCOLOGY | 2018年 / 14卷 / 03期
关键词：
chemo-immunotherapy; first-line; immune checkpoint inhibitors; immunotherapy; lung cancer; NSCLC; treatment naive; PACLITAXEL PLUS CARBOPLATIN; OPEN-LABEL; PHASE-III; PEMBROLIZUMAB; NIVOLUMAB; DOCETAXEL; CHEMOTHERAPY; MULTICENTER; IPILIMUMAB;
D O I：
10.2217/fon-2017-0124
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：191 / 194
页数：4
相关论文
共 50 条
[21]   Immune checkpoint inhibitors in non-small-cell lung cancer: current status and future directions [J].
Yan, Ya-fei ;
Zheng, Yong-fa ;
Ming, Ping-po ;
Deng, Xiao-xi ;
Ge, Wei ;
Wu, Yao-gui .
BRIEFINGS IN FUNCTIONAL GENOMICS, 2019, 18 (02) :147-156
[22]   Economic evaluation of docetaxel-gemcitabine versus vinorelbine-cisplatin combination as front-line treatment of patients with advanced/metastatic non-small-cell lung cancer in Greece: a cost-minimization analysis [J].
Maniadakis, N. ;
Fragoulakis, V. ;
Pallis, A. G. ;
Simou, E. ;
Georgoulias, V. .
ANNALS OF ONCOLOGY, 2010, 21 (07) :1462-1467
[23]   Combining Immunotherapy with Radiation Therapy in Non- Small Cell Lung Cancer [J].
Fitzgerald, Kelly ;
Simone, Charles B., II .
THORACIC SURGERY CLINICS, 2020, 30 (02) :221-239
[24]   Outcomes in Patients With Non-small-cell Lung Cancer With Brain Metastases Treated With Pembrolizumab-based Therapy [J].
Sun, Lova ;
Davis, Christiana W. ;
Hwang, Wei-Ting ;
Jeffries, Seth ;
Sulyok, Lydia Frenzel ;
Marmarelis, Melina E. ;
Singh, Aditi P. ;
Berman, Abigail T. ;
Feigenberg, Steven J. ;
Levin, William ;
Ciunci, Christine A. ;
Bauml, Joshua M. ;
Cohen, Roger B. ;
Langer, Corey J. ;
Aggarwal, Charu .
CLINICAL LUNG CANCER, 2021, 22 (01) :58-+
[25]   Targeting PD-L1 for non-small-cell lung cancer [J].
Feld, Emily ;
Horn, Leora .
IMMUNOTHERAPY, 2016, 8 (06) :747-758
[26]   New options on the horizon for nononcogene addicted non-small-cell lung cancer [J].
Paglialunga, Luca ;
Ricciardi, Serena ;
D'Arcangelo, Manolo .
FUTURE ONCOLOGY, 2018, 14 (13) :19-28
[27]   Immunotherapy in advanced non-small-cell lung cancer withEGFRmutations [J].
Liu, Fangfang ;
Yuan, Xun ;
Jiang, Jizong ;
Chu, Qian .
IMMUNOTHERAPY, 2020, 12 (16) :1195-1207
[28]   Update 2025: Management of Non-Small-Cell Lung Cancer [J].
Jeon, Hyein ;
Wang, Shuai ;
Song, Junmin ;
Gill, Harjot ;
Cheng, Haiying .
LUNG, 2025, 203 (01)
[29]   Neoadjuvant immunotherapy in resectable non-small-cell lung cancer [J].
Chen, Lanyi Nora ;
Wei, Alexander Z. ;
Shu, Catherine A. .
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
[30]   First line Immunotherapy for Non-Small Cell Lung Cancer [J].
Nasser, Nicola J. ;
Gorenberg, Miguel ;
Agbarya, Abed .
PHARMACEUTICALS, 2020, 13 (11) :1-24
12345